Izotropic Announces Debt Settlement
British Columbia and Sacramento, California--(Newsfile Corp. - April 21, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into a debt settlement agreement (the "Agreement") with a lender (the "Le
2026-04-21 2:09 PM EDT | Izotropic Corporation
Microbiome Labs relaunches BiomeFX to advance gut microbiome interpretation
Franklinton, North Carolina--(Newsfile Corp. - April 21, 2026) - Microbiome Labs™, a leader in microbiome-based solutions, today announced the relaunch of its BiomeFX™ Functional Microbiome Analysis in partnership with Jona, the AI-powered gut microbiome company. The interpretation layer of BiomeFX is now powered by Jona AI, a clinical-grade microbiome anal
2026-04-21 9:00 AM EDT | Microbiome Labs
Virica Biotech Introduces Viric.AI, an Active Learning Platform to Accelerate Biomanufacturing Optimization
Ottawa, Ontario--(Newsfile Corp. - April 21, 2026) - Virica Biotech ("Virica"), an Ottawa-based company focused on improving biomanufacturing through its Viral Sensitizers (VSE™) enhancer technology, today announced the launch of Viric.AI™, a proprietary active learning platform that accelerates the discovery of optimized biomanufacturing enhancers, as part of their service offering to clients. Developed in collaboration with Dr. Francesco Gentile's lab at the University of
2026-04-21 9:00 AM EDT | Virica Biotech Inc.
PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness
Toronto, Ontario--(Newsfile Corp. - April 21, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, today announced that it believes the recent U.S. executive order, "Accelerating Medical Treatments
Biotechnology, Pharmaceuticals
2026-04-21 8:00 AM EDT | PharmaTher Holdings Ltd.
Nualtis Corp. Announces Participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Montreal, Quebec--(Newsfile Corp. - April 20, 2026) - Nualtis Corp., a specialty pharmaceutical company focused on the development of innovative oral dissolvable film (ODF) drug delivery technologies, will be participating in the 2026 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 21 and 22 at the Metro Toronto Convention Centre.
Technology, Biotechnology, Investment Banking, Health
2026-04-20 11:41 AM EDT | Bloom Burton & Co. Inc.
Nextleaf Advances Capex-Light Model with New Micro-Processing Site Licence, Supporting Revenue Growth and Margin Expansion
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a multi-patented life science company and Canadian cannabis processor, is pleased to announce it has been granted a Health Canada Micro-Processing Licence for its second site of operations, Nextleaf Distribution. The issuance of this licence marks a key milestone in the Company's capex-light expansion strategy stre
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-04-20 9:00 AM EDT | Nextleaf Solutions Ltd.
PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides
Toronto, Ontario--(Newsfile Corp. - April 20, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical comp
Biotechnology, Pharmaceuticals
2026-04-20 8:00 AM EDT | PharmaTher Holdings Ltd.
Huxley Health Inc. Introduces Aerasyn Biotech Division, Expands Leadership and Scalable IP Platform, Engages Capital Partner for Up to $15M Financing and Prepares to Go Public Amid Growing U.S. Policy and Public Discourse on Psychedelics
Toronto, Ontario--(Newsfile Corp. - April 20, 2026) - Huxley Health Inc. ("Huxley" or the "Company"), together with its Aerasyn Biotech division, a biotechnology platform advancing next-generation therapeutics through AI-guided discovery, advanced synthesis, and proprietary formulation technologies, today announced a series of coordinated strategic developments that significantly strengthen its leadership team, intellectual property platform, and capital markets positioning.
2026-04-20 7:30 AM EDT | Huxley Health Inc.
Yellowbird Diagnostics to Present at the Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario--(Newsfile Corp. - April 20, 2026) - Yellowbird Diagnostics Inc. a clinical-stage biotechnology company developing next-generation metabolic imaging agents to detect disease earlier and guide clinical decision-making, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada. Nick Calvert, Chief Executive Officer, and Michael Gottlieb, Ex
Technology, Biotechnology, Investment Banking, Health
2026-04-20 7:15 AM EDT | Bloom Burton & Co. Inc.
Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today launched its Ibogaine Initiative, a program to extend the Company's Health Canada-licensed GMP platform to include the manufacture and supply of ibogaine. The initiative comes as the United States has, for the first time, taken ini
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-04-20 6:00 AM EDT | Optimi Health Corp.
Optimi Health startet Ibogaine-Initiative, da US-Executive Order einen Weg für psychedelische Arzneimittelprodukte signalisiert
Vancouver, British Columbia--(Newsfile Corp. - Montag, 20. April 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (das "Unternehmen" oder "Optimi"), ein kommerziell tätiger pharmazeutischer Hersteller regulierter psychedelischer Arzneimittelprodukte, gab heute den Start seiner Ibogaine-Initiative bekannt. Ziel des Programms ist es, die nach GMP lizenzierte Plattform des Unternehmens mit Health-Canada-Zulassung auf die Herstellung und Lieferung von Ibogaine auszuwe
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-04-20 2:00 AM EDT | Optimi Health Corp.
Northwyn Wellness Group Announces Participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Vancouver, British Columbia--(Newsfile Corp. - April 19, 2026) - Northwyn Wellness Group, Canada's operator-led platform for medical aesthetics, dermatology, preventative medicine, and wellness clinics, will be participating in the 2026 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 21 and 22 at the Metro Toronto Convention Centre.
Technology, Biotechnology, Investment Banking, Health
2026-04-19 6:00 PM EDT | Bloom Burton & Co. Inc.
American Aires Provides Update on Liquidity Position, Strategic Review and Ongoing Litigation
Toronto, Ontario--(Newsfile Corp. - April 17, 2026) - American Aires Inc. (CSE: WIFI) (OTCQB: AAIRF) (the "Company") issues this update regarding its liquidity position, its ongoing strategic review, and its previously disclosed litigation. As previously disclosed, the Company is pursuing legal proceedings against certain former officers and related parties (the "Litigation") in connection with alleged misconduct and related matters. The Litigation is ongoing, and the Comp
2026-04-17 8:00 PM EDT | American Aires Inc.
Sharp Therapeutics Corp. Announces Fourth Quarter 2025 Results, Closing of Convertible Note Offering and Adoption of Semi-Annual Reporting
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 17, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its annual audited consolidated financial statements for the year ended December 31, 2025, and related management discussion and analysis ("MD&A") and annual information form. All dollar figures are in United States dollars, unless otherwise stated. Scott Sneddon, Sh
2026-04-17 6:13 PM EDT | Sharp Therapeutics Corp.
Marvel Biosciences Announces Closing of Convertible Debenture Offering
Calgary, Alberta--(Newsfile Corp. - April 17, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today that it has completed the closing of the previously announced non-brokered private placement of unsecured convertible debentures ("Debentures") for gross proceeds of $500,000 (the "Offering"), subject to final approval of the TSX Venture Exchange. The Debentures bear interest at the rate of twelve percent (12%) per ann
2026-04-17 4:30 PM EDT | Marvel Biosciences Corp.
Richards Group Inc. Announces Participation in The 2026 Bloom Burton & Co. Healthcare Investor Conference
Mississauga, Ontario--(Newsfile Corp. - April 17, 2026) - Richards Group Inc. (TSX: RIC) will be participating in the 2026 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 21 and 22 at the Metro Toronto Convention Centre.
Technology, Biotechnology, Investment Banking, Health
2026-04-17 1:32 PM EDT | Bloom Burton & Co. Inc.
Envoy Medical Appoints Chas McKhann to Board of Directors
White Bear Lake, Minnesota--(Newsfile Corp. - April 16, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, today announced the appointment of Chas McKhann, a seasoned medical technology executive with documented success, to its Board of Directors. Mr. McKhann is a well-known and respected med tech leader with extensive experience cre
Biotechnology, Healthcare and Hospitals
2026-04-16 8:00 AM EDT | Envoy Medical, Inc.
PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery
Toronto, Ontario--(Newsfile Corp. - April 16, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on microneedle patch technologies and peptide-enabled product oppor
Biotechnology, Pharmaceuticals
2026-04-16 8:00 AM EDT | PharmaTher Holdings Ltd.
OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes
New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular immune responses Company to host conference call later in April 2026 to review new biomarker signature Biomarker signature meets pharmacodynamic/response criteria established by FDA's Biomarkers, EndpointS and other Tools (BEST) program for use as a surrogate clinical endpo
2026-04-16 7:20 AM EDT | OS Therapies
Resverlogix Corp. Announces Filing of Annual Filings and Revocation of MCTO
Calgary, Alberta--(Newsfile Corp. - April 16, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announces the revocation, effective April 15, 2026, of a management cease trade order ("MCTO") issued by the Alberta Securities Commission (the "ASC") on April 1, 2026 at the request of the Company. The Company filed its audited financial statements, management's discussion & analysis, certifications of annual filings, and annual information form for the year
Technology, Biotechnology, Healthcare and Hospitals
2026-04-16 7:15 AM EDT | Resverlogix Corp.